Prestige Consumer Healthcare Inc.
PBH Healthcare Drug Manufacturers Specialty & Generic
Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025.
- Revenue
- +22.7%
- EPS
- −38.4%
- Free cash flow
- −38.2%
- Total debt
- +100.9%
Quarter to September 2026, against a year earlier
Follow PBH
Alert me
Prestige Consumer Healthcare Inc. (PBH) EV/FCF
As of 5 November 2026, Prestige Consumer Healthcare Inc. (PBH) trades at a EV/FCF of 19.2×. Over the past ten years it has ranged from 12.6× (September 2015) to 35.9× (April 2017); the current reading is higher than 56% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2026 | 15.5× | (27.25%) |
| FY2025 | 21.4× | 9.83% |
| FY2024 | 19.5× | (2.41%) |
| FY2023 | 19.9× | 20.97% |
| FY2022 | 16.5× | (4.35%) |
| FY2021 | 17.2× | (0.52%) |
| FY2020 | 17.3× | (6.40%) |
| FY2019 | 18.5× | (1.78%) |
| FY2018 | 18.8× | (46.20%) |
| FY2017 | 35.0× | 37.00% |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 19.5× | 9.28% |
| Jun 2026 | 17.8× | 14.54% |
| Mar 2026 | 15.5× | 5.03% |
| Dec 2025 | 14.8× | (4.61%) |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| AMLX Amylyx Pharmaceuticals, Inc. compare | −21.7× |
| ALVO Alvotech compare | −11.9× |
| RGC Regencell Bioscience Holdings Limited compare | 0.9× |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 6.6× |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 7.5× |
| TRLV Trulieve Cannabis Corp. compare | 12.0× |
| PBH Prestige Consumer Healthcare Inc. | 19.2× |
| PRGO Perrigo Company plc compare | 28.6× |
| XERS Xeris Biopharma Holdings, Inc. compare | 33.9× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on PBH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement